AskBio/Bayer Deal History & Licensing Activity
AskBio/Bayer is a large pharma headquartered in Germany. Over the past three years, AskBio/Bayer has been involved in 3 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 3 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
3
Top Modality
Other
Focus Area
Metabolic
AskBio/Bayer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AskBio/Bayer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Eye implant for glaucoma and diabetic retinopathy | Bayer | Other | Unknown | acquisition | May 28, 2026 |
| AB-1009 | Genethon | Gene Therapy | Unknown | license | Apr 11, 2026 |
AskBio/Bayer Pipeline Focus
Therapeutic areas and modalities where AskBio/Bayer is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
AskBio/Bayer Clinical Pipeline
AskBio/Bayer has 3 active clinical trials across 2 development phases.
1
Phase 1
2
Phase 2
See How Your Asset Matches AskBio/Bayer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About AskBio/Bayer Licensing & Deal Activity
AskBio/Bayer is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, AskBio/Bayer ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AskBio/Bayer include Metabolic (2 deals and trials), Rare Disease (2 deals and trials), CNS Disorders (2 deals and trials), and Cardiovascular (1 deal and trial). In terms of modality, AskBio/Bayer has shown particular interest in other, gene therapy, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AskBio/Bayer and 850+ other biopharma companies. Use our Solidus to benchmark your asset against AskBio/Bayer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.